switching from semaglutide to liraglutide Vs | Wegovy Vs Saxenda Switching between GLP‐1 receptor agonists

Waj Mehal is a professor of medicine at Yale School of Medicine, an obesity medicine doctor and director of the Fatty Liver Program and Yale Metabolic Health and Weight Loss Program

GLP-1 medications (Zepbound, Wegovy) produce significantly greater long-term weight loss, have metabolic and cardiovascular benefits, are approved for chronic use, and are more appropriate for patients with obesity-related health conditions who need ongoing treatment

Footnotes Some typos in the text and references that pointed to the wrong papers have been fixed

Pricing Pressure Becomes Part of the System If the early GLP-1 era was defined by sticker shock, 2026 marks the point where pricing pressure becomes structural

Semaglutide, marketed under brand names including Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management and chronic weight management

Laboratory studies have explored its role in: Cell culture and proliferation assays Molecular binding and receptor interaction studies Tissue regeneration and wound healing models Biochemical pathway analysis Pharmacokinetic and stability profiling Note: GLP-3RT sold by CoreVionRX is intended strictly for research purposes